From Tech Transfer To Validation: One CDMO's Client-Centric Approach To Development

As the biopharmaceutical landscape expands to accommodate global markets, drug sponsors are seeking reliable and experienced partners to navigate the complexities of drug development and manufacturing. Though it may not be widely recognized as a hub for biomanufacturing, Poland is emerging as an affordable location to outsource biologic manufacturing. Poland abides by the EMA’s reliable regulatory framework while boasting economic stability and a skilled workforce. Mabion, a leading Polish CDMO, offers a comprehensive range of services, from early-stage development to commercial manufacturing.

In this Q&A article, a panel of Mabion's subject matter experts delve into how they structure their client-centric approach to projects. In particular, Mabion highlights their commitment to collaboration, technical expertise, and adherence to regulatory standards. Readers will gain greater insight into the proposal process, the components of a robust risk mitigation strategy, technology transfer, and process development. Download the full article to learn more about Mabion's approach to the drug development journey.